[go: up one dir, main page]

PE20010529A1 - Moduladores de los receptores activados del proliferador de peroxisomas - Google Patents

Moduladores de los receptores activados del proliferador de peroxisomas

Info

Publication number
PE20010529A1
PE20010529A1 PE2000000876A PE0008762000A PE20010529A1 PE 20010529 A1 PE20010529 A1 PE 20010529A1 PE 2000000876 A PE2000000876 A PE 2000000876A PE 0008762000 A PE0008762000 A PE 0008762000A PE 20010529 A1 PE20010529 A1 PE 20010529A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
etoxy
methyloxazole
acid
Prior art date
Application number
PE2000000876A
Other languages
English (en)
Inventor
Dawn A Brooks
Christopher J Rito
Anthony J Shuker
Samuel J Dominianni
Alan M Warshawsky
Lynn S Gossett
Donald P Matthews
David A Hay
Robert J Ardecky
Pierre-Yves Michellys
John S Tyhonas
Original Assignee
Ligand Pharm Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc, Lilly Co Eli filed Critical Ligand Pharm Inc
Publication of PE20010529A1 publication Critical patent/PE20010529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE BIARIL OXAZOLES DE FORMULA I, DONDE n ES 2-4; V ES O, S; W ES O, S, SO2; R1 ES H, ALQUILO C1-C4, FENILO, TRIFLUOROMETILO; R2 ES H, ALQUILO C1-C6, ARIL-ALQUILO C1-C6, ENTRE OTROS; R3 ES H, ALQUILO C1-C6, ARIL-ALQUILO C1-C6, ENTRE OTROS; R4 ES H, ALQUILO C1-C4, ARILO, BENCILO; R5 ES H, ARILO, HETEROARILO; R6 ES H, ALQUILO C1-C4, AMINOALQUILO. SON COMPUESTOS PREFERIDOS ACIDO 2-{4-[2-(2-BIFENIL-4-IL-5-METILOXAZOL-4-IL)ETOXI]NAFTALEN-1-ILOXI}-2-METILPROPIONICO, ACIDO 2-{4-[2-(2-BIFENIL-4-IL-5-METILOXAZOL-4-IL)ETOXI]-5,6,7,8-TETRAHIDRONAFTALEN-1-ILOXI}-2-METIL-PROPIONICO, ACIDO 2-{3-[2-(2-ARILFENILOXAZOL-5-SUSTITUIDO-4-IL)ETOXI]2-FENOXI}ETANOICO, ACIDO 2-(4-{2-[2-(4-TIOFEN-2-IL-FENIL)-5-METILOXAZOL-4-IL]ETOXI}FENOXI)-2-METILPROPIONICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE 2-(BROMOFENIL)-4-(2-HIDROXIETIL)OXAZOL-5 SUSTITUIDO. EL COMPUESTO I ES UN MODULADOR DEL RECEPTOR þ ACTIVADO DEL PROLIFERADOR DE PEROXISOMAS, REDUCE LOS TRIGLICERIDOS Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DIABETES MELLITUS, SINDROME X
PE2000000876A 1999-08-27 2000-08-25 Moduladores de los receptores activados del proliferador de peroxisomas PE20010529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15116299P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
PE20010529A1 true PE20010529A1 (es) 2001-05-18

Family

ID=22537578

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000876A PE20010529A1 (es) 1999-08-27 2000-08-25 Moduladores de los receptores activados del proliferador de peroxisomas

Country Status (13)

Country Link
US (3) US6417212B1 (es)
EP (1) EP1206457B1 (es)
JP (1) JP2003508389A (es)
AR (1) AR025386A1 (es)
AT (1) ATE252091T1 (es)
AU (1) AU7073400A (es)
CA (1) CA2382966A1 (es)
DE (1) DE60005973T2 (es)
DK (1) DK1206457T3 (es)
ES (1) ES2204684T3 (es)
PE (1) PE20010529A1 (es)
PT (1) PT1206457E (es)
WO (1) WO2001016120A1 (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
AU8588798A (en) * 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
AU2000265105A1 (en) * 2000-08-02 2002-02-13 Pharmanutrients Methods and compositions for the prevention and treatment of syndrome x
AU2001277723A1 (en) 2000-08-11 2002-02-25 Nippon Chemiphar Co., Ltd. Ppardelta activators
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
PT1313716E (pt) 2000-08-23 2007-07-11 Lilly Co Eli Derivados do ácido oxazolil-arilpropiónico e a sua utilização como agonistas do ppar
EP1313717B1 (en) * 2000-08-23 2007-10-17 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CZ305202B6 (cs) 2001-01-26 2015-06-10 Merck Sharp & Dohme Corp. Farmaceutický prostředek
RU2356550C2 (ru) 2001-01-26 2009-05-27 Шеринг Корпорейшн Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
KR20040012905A (ko) * 2001-06-07 2004-02-11 일라이 릴리 앤드 캄파니 페록시좀 증식제 활성화 수용체의 조절제
SK14922003A3 (sk) 2001-06-07 2005-04-01 Eli Lilly And Company Modulátory receptorov aktivovaných proliferátormi peroxizómov (PPAR)
US20110065129A1 (en) 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
KR100901683B1 (ko) 2001-08-10 2009-06-08 닛뽕 케미파 가부시키가이샤 퍼옥시좀 증식제 응답성 수용체 δ의 활성화제
MXPA04002330A (es) 2001-09-14 2005-04-08 Japan Tobacco Inc Compuestos biarilo ligados.
AU2002336609B2 (en) 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
GB0127916D0 (en) * 2001-11-21 2002-01-16 Rowett Res Inst Method
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
EP1453811A2 (en) * 2001-11-30 2004-09-08 Eli Lilly And Company Peroxisome proliferator activated receptor agonists
WO2003072102A1 (en) 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
WO2003091211A1 (en) * 2002-03-28 2003-11-06 Sumitomo Pharmaceuticals Co., Ltd. Novel heteroaryl compounds
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US7220880B2 (en) 2002-06-19 2007-05-22 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7192970B2 (en) * 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
WO2004063166A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heterocyclic ppar modulators
AU2004207444B2 (en) * 2003-01-17 2008-07-31 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
ATE382043T1 (de) 2003-02-14 2008-01-15 Lilly Co Eli Sulfonamid-derivate als ppar-modulatoren
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JPWO2004080943A1 (ja) * 2003-03-11 2006-06-08 小野薬品工業株式会社 シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
EP1666472B1 (en) * 2003-09-22 2012-08-01 Ono Pharmaceutical Co., Ltd. Phenylacetic acid derivative, process for producing the same, and use
ES2287786T3 (es) * 2003-10-31 2007-12-16 Janssen Pharmaceutica N.V. Derivados de acido fenoxiacetico utiles como agonistas dobles del receptor activado por el proliferador de peroxisomas (ppar).
US20070208021A1 (en) * 2004-03-30 2007-09-06 Daiichi Pharmaceutical Co., Ltd. Phenoxyacetic Acid Derivatives and Drug Comprising The Same
DE602005014629D1 (de) * 2004-04-28 2009-07-09 Hoffmann La Roche Pyrazolphenylderivate als ppar-aktivatoren
CN100344618C (zh) 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
BRPI0515209A (pt) * 2004-08-17 2008-07-08 Galderma Reseach & Dev S N C compostos, composição cosmética, usos de uma composição e composição farmacêutica
FR2874378B1 (fr) * 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
FR2874379B1 (fr) * 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
KR20070047308A (ko) 2004-08-17 2007-05-04 갈데르마 리써어치 앤드 디벨로프먼트 Ｐｐａｒ 유형 수용체를 활성화시키는 신규 이방향족화합물, 및 미용 또는 약학적 조성물에서의 그의 용도
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
PT1817282E (pt) 2004-11-23 2011-09-19 Astrazeneca Ab Derivados do ácido fenoxiacético úteis para tratar doenças respiratórias
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
US20080255150A1 (en) * 2005-11-05 2008-10-16 Astrazeneca Ab Novel Compounds
EP1963259B1 (en) * 2005-12-15 2012-02-15 AstraZeneca AB Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
US8023825B2 (en) * 2006-04-04 2011-09-20 Cisco Technology, Inc. Optical switching architectures for nodes in WDM mesh and ring networks
NZ572268A (en) 2006-04-18 2011-09-30 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta (ppar)
EP2030974B1 (en) * 2006-06-13 2016-02-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Thiazole non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
UA100983C2 (ru) * 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
PT2277874T (pt) 2008-04-15 2018-08-10 Nippon Chemiphar Co Ativador para recetor ativado por proliferador de peroxissoma
AR073949A1 (es) * 2008-10-21 2010-12-15 Metabolex Inc Agonistas del receptor aril-gpr120 y usos de los mismos
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
LT3193901T (lt) 2014-12-23 2018-06-11 4D Pharma Research Limited Pirino polipeptidas ir imuninė moduliacija
EP3065748B1 (en) 2014-12-23 2017-11-22 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ES2748812T3 (es) 2015-06-15 2020-03-18 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3240554T (pt) 2015-06-15 2019-11-04 4D Pharma Res Ltd Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes
RS63089B1 (sr) 2015-06-15 2022-04-29 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
SI3209310T1 (en) 2015-11-20 2018-06-29 4D Pharma Research Limited Compositions containing bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
TWI787272B (zh) 2017-05-22 2022-12-21 英商4D製藥研究有限公司 包含細菌菌株之組合物
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
SG11201912105PA (en) 2017-06-14 2020-01-30 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1993021166A1 (en) * 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
PL174610B1 (pl) 1992-07-03 1998-08-31 Smithkline Beecham Plc Nowe związki heterocykliczne
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
EP0815230A2 (en) 1995-03-20 1998-01-07 Ligand Pharmaceuticals, Inc. MODULATORS OF ob GENE AND SCREENING METHODS THEREFOR
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
JPH08325264A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−芳香環置換−３−フェニルプロピオン酸またはアクリル酸誘導体
JPH08325250A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
KR19990045756A (ko) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 Ｒｘｒ 작용제를 이용하는 ｎｉｄｄｍ 치료 방법
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
ES2202582T3 (es) * 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2749583B1 (fr) * 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
CN1233241A (zh) 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
EP1005344A4 (en) * 1996-12-31 2003-03-19 Salk Inst For Biological Studi TREATMENT OF LIPOSARCOMES USING A COMBINATION OF THIAZOLIDINEDIONES AND SELECTIVE AGONISTS OF RETINO X RECEPTORS
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
AU6773598A (en) * 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
US6166192A (en) * 1997-05-30 2000-12-26 Dana-Farber Cancer Institute PGC-1, a novel brown fat PPARγ coactivator
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU8588798A (en) * 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
WO1999020275A1 (en) * 1997-10-17 1999-04-29 Aventis Pharmaceuticals Products Inc. Therapeutic uses of quinoline derivatives
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999029317A1 (en) * 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes
TR200001753T2 (tr) * 1997-12-19 2000-11-21 Merck & Co., Inc. Ariltiazolidindion türevleri.
WO1999038850A1 (en) * 1998-01-29 1999-08-05 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
GB2335597A (en) 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
AU3333399A (en) * 1998-04-06 1999-10-25 Janssen Pharmaceutica N.V. Nucleotide sequence expressing human fatty acid transport protein and corresponding aminoacid sequence. use for the regulation of fatty acids metabolism
NZ508066A (en) * 1998-05-11 2003-03-28 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
PL345627A1 (en) * 1998-07-21 2002-01-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AR025386A1 (es) 2002-11-27
US6417212B1 (en) 2002-07-09
US6825222B2 (en) 2004-11-30
DE60005973D1 (de) 2003-11-20
EP1206457A1 (en) 2002-05-22
US20030045558A1 (en) 2003-03-06
DK1206457T3 (da) 2004-02-16
DE60005973T2 (de) 2004-05-13
EP1206457B1 (en) 2003-10-15
ES2204684T3 (es) 2004-05-01
WO2001016120A9 (en) 2002-07-11
US20040019090A1 (en) 2004-01-29
CA2382966A1 (en) 2001-03-08
US6610696B2 (en) 2003-08-26
JP2003508389A (ja) 2003-03-04
ATE252091T1 (de) 2003-11-15
AU7073400A (en) 2001-03-26
WO2001016120A1 (en) 2001-03-08
PT1206457E (pt) 2004-03-31

Similar Documents

Publication Publication Date Title
PE20010529A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
PE20000947A1 (es) ACTIVADORES DE hPPARþ Y hPPARO
PE20010406A1 (es) ACIDO 2-{2-METIL-4[({4-METIL-2[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO COMO AGONISTA DEL hPPARd
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
PE20021152A1 (es) Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma
PE20030326A1 (es) Derivados del acido indan acetico y su uso como agentes farmaceuticos, intermediarios y metodo de preparacion
RU2312106C2 (ru) Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar
PE20040516A1 (es) Derivados de 1,2-azol
PE20011010A1 (es) Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
PE20030989A1 (es) Derivados de tiazol y oxazol que modulan la actividad de ppar
PE20021117A1 (es) Compuestos agonistas del receptor activador del proliferador de peroxisomas (ppar)
JP2006511612A5 (es)
RU2006103493A (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
PE20030414A1 (es) Derivados de diarilcicloalquilo y procedimiento para su preparacion
PE20011056A1 (es) Acidos ariloxiaceticos para la diabetes y trastornos de los lipidos
RU99105567A (ru) Производные пропионовой кислоты и их использование
PE20060352A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos
PE20040190A1 (es) Tiazoles y oxazoles sustituidos que modulan la actividad de ppar
AU2001277723A1 (en) Ppardelta activators
RU2000128033A (ru) Гетероциклические производные глицил-бета-аланина в качестве антагонистов витронектина
PE20030925A1 (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
IT1231413B (it) Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
JP2006514069A (ja) Ｐｐａｒ調節因子としての融合複素環式誘導体
US6288096B1 (en) Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
RU2006106922A (ru) Амидное производное

Legal Events

Date Code Title Description
FC Refusal